NEW YORK (GenomeWeb News) – Accelr8 today disclosed that revenues during its fiscal third quarter fell 18-fold quarter over quarter, resulting from the end of an agreement with Novartis.

In its Form 10-Q filed with the US Securities and Exchange Commission, the Denver-based company reported revenues of $13,207 for the three months ended April 30, compared to $240,272 a year ago, as technical development fees came in at $0 for the recent quarter, down from $214,500 a year ago.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: the Human Silencing Hub protein complex, and more.

Heads of various research funding agencies discuss how to encourage scientific breakthroughs, ScienceInsider reports.

The Kansas City Star examines issues surrounding newborn genome sequencing.

Researchers say their Research Resource Identifier citation format is catching on, Nature News reports.